Commentary on: Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trialNavarra SV, Guzm án RM, Gallacher AE, et al. Lancet. 2011;377(9767):721-731
Question: In patients with serologically active systemic lupus erythematosus (SLE), does the addition of belimumab to standard care improve disease activity?
Design: Double-blind, parallel-group, randomized, placebo-controlled trial.
Gamble RG, Dellavalle RP. A Randomized Controlled Trial of Belimumab for the Treatment of Active Systemic Lupus Erythematosus. Arch Dermatol. 2012;148(3):376–378. doi:10.1001/archdermatol.2011.1266